Second primary malignancies among cancer patients.
SEER
Second primary malignancy (SPM)
epidemiological investigation
median survival time
standard incidence rate (SIR)
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
entrez:
23
6
2020
pubmed:
23
6
2020
medline:
23
6
2020
Statut:
ppublish
Résumé
Rate of second primary malignancies (SPM) is steadily increasing over the last decades. New therapies, early diagnostic markers, screening tests for a larger number of individuals contribute to the increase prevalence of SPM. In the current study, we try to described the demographic composition of SPM victims, distribution of primary sites, and the impact of related factors on prognosis. We conducted a retrospective study identifying patients over the age of 18 who were diagnosed with SPM from the 16 most common cancer sites between 2000 and 2013 from Surveillance, Epidemiology, and End Results data. Cox proportional hazards regression was used to analyze the relationship between different factors associated to the prognosis of SPM. Standard incidence rate of multiple primary (MP-SIR) was also calculated. A total of 303,753 patients were diagnosis with SPM and 76,168 of whom (25.08%) were included in our analytic cohort. Patients with prostate cancer was vulnerable to SPM, accounting for 34.59%, and SPM was prone to occur in lung and bronchus, accounting for 24.90%. The heat map shows that esophagus cancer survivors have the highest risk of developing stomachache tumors (SIR =5.08). The result of Cox regression suggests that a history of liver was associated with the shortest survival time (HR =1.64, 95% CI, 1.54-1.75, P<0.001). With the advancement of medical standards, the survival time of cancer patients is prolonged, but the occurrence of SPM is also increasing, and the prognosis is not optimistic. More attention needs to be invested in the prevention and treatment of SPM.
Sections du résumé
BACKGROUND
BACKGROUND
Rate of second primary malignancies (SPM) is steadily increasing over the last decades. New therapies, early diagnostic markers, screening tests for a larger number of individuals contribute to the increase prevalence of SPM. In the current study, we try to described the demographic composition of SPM victims, distribution of primary sites, and the impact of related factors on prognosis.
METHODS
METHODS
We conducted a retrospective study identifying patients over the age of 18 who were diagnosed with SPM from the 16 most common cancer sites between 2000 and 2013 from Surveillance, Epidemiology, and End Results data. Cox proportional hazards regression was used to analyze the relationship between different factors associated to the prognosis of SPM. Standard incidence rate of multiple primary (MP-SIR) was also calculated.
RESULTS
RESULTS
A total of 303,753 patients were diagnosis with SPM and 76,168 of whom (25.08%) were included in our analytic cohort. Patients with prostate cancer was vulnerable to SPM, accounting for 34.59%, and SPM was prone to occur in lung and bronchus, accounting for 24.90%. The heat map shows that esophagus cancer survivors have the highest risk of developing stomachache tumors (SIR =5.08). The result of Cox regression suggests that a history of liver was associated with the shortest survival time (HR =1.64, 95% CI, 1.54-1.75, P<0.001).
CONCLUSIONS
CONCLUSIONS
With the advancement of medical standards, the survival time of cancer patients is prolonged, but the occurrence of SPM is also increasing, and the prognosis is not optimistic. More attention needs to be invested in the prevention and treatment of SPM.
Identifiants
pubmed: 32566575
doi: 10.21037/atm-20-2059
pii: atm-08-10-638
pmc: PMC7290649
doi:
Types de publication
Journal Article
Langues
eng
Pagination
638Informations de copyright
2020 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-2059). XL serves as an unpaid section editor of Annals of Translational Medicine from Jan 2020 to Dec 2021. The other authors have no conflicts of interest to declare.
Références
Int J Cancer. 2020 Jan 15;146(2):352-362
pubmed: 30861567
BMJ. 2016 Mar 02;352:i851
pubmed: 26936410
Lancet Oncol. 2011 Apr;12(4):353-60
pubmed: 21454129
Hematol Oncol. 2017 Dec;35(4):599-607
pubmed: 27238496
IARC Sci Publ. 1987;(82):1-406
pubmed: 3329634
Thyroid. 2017 Jun;27(6):793-801
pubmed: 28338430
PLoS One. 2016 Jan 14;11(1):e0139782
pubmed: 26766567
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cancer. 2014 May 15;120(10):1507-13
pubmed: 24863390
J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65
pubmed: 16174857
Int J Cancer. 2019 Jul 1;145(1):143-153
pubmed: 30613963
Thyroid. 2017 Aug;27(8):1068-1076
pubmed: 28614983
Cancer Causes Control. 2019 May;30(5):465-475
pubmed: 30900065
Biosci Rep. 2019 Jun 14;39(6):
pubmed: 31138756
Cancer. 1979 May;43(5 Suppl):1962-6
pubmed: 445384
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):561-70
pubmed: 23535024
Ann Intern Med. 2010 Oct 5;153(7):442-51
pubmed: 20921543
J Natl Cancer Inst. 2006 Jan 4;98(1):15-25
pubmed: 16391368
J Natl Cancer Inst. 2012 Mar 7;104(5):357-70
pubmed: 22312134
Urol Int. 2014;93(3):279-88
pubmed: 25139441
World J Gastroenterol. 2015 Jul 21;21(27):8358-65
pubmed: 26217087
J Clin Oncol. 2012 Oct 20;30(30):3734-45
pubmed: 23008293
Gastric Cancer. 2016 Apr;19(2):490-497
pubmed: 25772342
J Cancer Res Clin Oncol. 2015 Nov;141(11):1995-2004
pubmed: 25971624
Thyroid. 2015 Jun;25(6):681-7
pubmed: 25851829
JAMA Oncol. 2016 Dec 1;2(12):1624-1627
pubmed: 27711914
Adv Hematol. 2012;2012:801495
pubmed: 22851973